eltrombopag olamine

{
  "id": "MLC-T-ONC-002757",
  "term": "eltrombopag olamine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat thrombocytopenia (a low blood platelet count) in adults and children with chronic immune thrombocytopenic purpura that did not get better with other treatment. Eltrombopag olamine is also used to treat severe aplastic anemia. It is also being studied in the treatment of other conditions and types of cancer. Eltrombopag olamine binds to the thrombopoietin receptor, which causes the bone marrow to make more platelets. It is a type of thrombopoietin receptor agonist. Also called Promacta.",
    "The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production."
  ],
  "synonyms": [
    "Promacta"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/eltrombopag-olamine/"
}